Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Valganciclovir
Brand Name
Valganciclovir
Generic Name
Valganciclovir
Active Ingredient
ValganciclovirCategory
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
Salt Form
Hydrochloride
Variants
9
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Valganciclovir, you must consult a qualified healthcare professional.
| 450 mg/1 | TABLET | ORAL | 27241-158 |
| 450 mg/1 | TABLET, FILM COATED | ORAL | 31722-832 |
| 450 mg/1 | TABLET, FILM COATED | ORAL | 55111-762 |
| 50 mg/mL | FOR SOLUTION | ORAL | 71151-003 |
| 450 mg/1 | TABLET, FILM COATED | ORAL | 68084-965 |
| 450 mg/1 | TABLET, FILM COATED | ORAL | 0904-6796 |
Detailed information about Valganciclovir
Valganciclovir is a potent antiviral prodrug and a Cytomegalovirus (CMV) nucleoside analog DNA polymerase inhibitor, primarily used to treat CMV retinitis in patients with AIDS and to prevent CMV disease in high-risk organ transplant recipients.
The dosage of Valganciclovir is strictly dependent on the condition being treated and the patient's renal function. According to the standard prescribing information:
Valganciclovir is approved for the prevention of CMV disease in pediatric kidney transplant recipients (aged 4 months to 16 years) and heart transplant recipients (aged 1 month to 16 years). The dose is calculated using a specific formula based on the child's Body Surface Area (BSA) and renal function (CrCl), often referred to as the modified Schwartz formula.
If the calculated CrCl exceeds 150 mL/min/1.73 m², a maximum value of 150 is used in the formula. The maximum daily dose for children should not exceed 900 mg. Healthcare providers must recalculate this dose frequently as the child's weight or kidney function changes.
Since Valganciclovir is primarily cleared by the kidneys, dose adjustments are mandatory for patients with a Creatinine Clearance (CrCl) below 60 mL/min. Failure to adjust the dose can lead to severe toxicity, including profound bone marrow suppression.
The safety and efficacy of Valganciclovir have not been specifically studied in patients with hepatic (liver) impairment. However, since the liver is involved in the conversion of Valganciclovir to ganciclovir, clinicians exercise caution, though no specific dose adjustments are currently mandated by the FDA.
Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased renal function in this population.
If a dose is missed, it should be taken as soon as the patient remembers. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Patients should never 'double up' on doses to make up for a missed one, as this increases the risk of bone marrow toxicity.
An overdose of Valganciclovir can be life-threatening. Symptoms of overdose typically mirror the drug's most severe side effects, including:
In the event of an overdose, the patient should be taken to an emergency room immediately. Hemodialysis and hydration may be used to reduce blood levels of ganciclovir.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this can lead to viral resistance or disease progression.
Valganciclovir is a potent medication, and side effects are frequent, particularly in patients who are already immunocompromised. The following are commonly reported:
Valganciclovir is a high-alert medication that requires close clinical supervision. It is not a cure for CMV; it is a treatment to suppress the virus. Patients must understand that the virus may remain dormant in the body and can reactivate if the medication is stopped or if the immune system weakens further.
As noted in the side effects section, Valganciclovir carries the FDA's most serious warning. This includes Hematologic Toxicity (the risk of life-threatening low blood counts), Impairment of Fertility (potential permanent infertility in men and women), Fetal Toxicity (severe birth defects), and Mutagenesis/Carcinogenesis (potential to cause cancer). These warnings are based on extensive animal data and clinical reports of bone marrow suppression in humans.
Valganciclovir is considered highly dangerous during pregnancy. In animal studies, ganciclovir caused cleft palate, small eyes (anophthalmia/microphthalmia), brain swelling (hydrocephalus), and abnormalities of the skeleton and reproductive system.
It is not known whether Valganciclovir or ganciclovir is excreted in human milk. However, because of the potential for serious adverse reactions in nursing infants (including carcinogenicity and bone marrow suppression), the CDC recommends that HIV-infected mothers do not breastfeed to avoid postnatal transmission of HIV. Furthermore, mothers taking Valganciclovir are generally advised to discontinue nursing.
Valganciclovir is an L-valyl ester prodrug of ganciclovir. Its antiviral activity is due to its conversion to ganciclovir, which is then phosphorylated to ganciclovir triphosphate. This active metabolite inhibits viral DNA synthesis by two mechanisms:
This process is highly selective for CMV-infected cells because the initial phosphorylation step requires the viral enzyme pUL97.
The pharmacodynamic effect of Valganciclovir is directly related to the plasma concentration of ganciclovir. Because Valganciclovir is a prodrug, its onset of action depends on the rate of conversion, which is nearly instantaneous upon absorption. The duration of effect is maintained by daily or twice-daily dosing, which keeps ganciclovir levels above the 50% inhibitory concentration (IC50) for most CMV strains. Viral resistance can develop through mutations in the pUL97 gene (preventing phosphorylation) or the UL54 gene (altering the DNA polymerase).
Common questions about Valganciclovir
Valganciclovir is primarily used to treat Cytomegalovirus (CMV) retinitis in people with AIDS, which is a viral infection that can cause blindness. It is also used to prevent CMV disease in patients who have received a kidney, heart, or kidney-pancreas transplant and are at high risk for the infection. By inhibiting the virus's ability to replicate its DNA, the drug prevents the spread of the infection to healthy tissues. It is an oral prodrug that the body quickly converts into the active antiviral medication, ganciclovir. Because it is a potent medication with significant risks, it is reserved for these specific, serious conditions.
The most common side effects include gastrointestinal issues like diarrhea, nausea, and vomiting, which affect a large percentage of patients. Many people also experience fever, fatigue, and headaches during treatment. More seriously, the drug often causes a significant drop in blood cell counts, leading to anemia (low red blood cells) and neutropenia (low white blood cells). These hematologic effects can increase the risk of infections and bleeding. Because of these risks, patients must undergo regular blood tests to monitor their health while taking the medication.
There is no known direct interaction between alcohol and Valganciclovir, but caution is highly recommended. Alcohol can cause dehydration and put extra stress on the kidneys, which are responsible for clearing Valganciclovir from your system. Additionally, both alcohol and the medication can cause dizziness, nausea, and stomach upset, potentially worsening these side effects. Since you are likely taking this drug for a serious condition or after an organ transplant, it is best to avoid alcohol to allow your body to heal and to keep your immune system as strong as possible. Always consult your doctor before consuming alcohol with any prescription medication.
No, Valganciclovir is not considered safe during pregnancy and is known to cause severe birth defects based on animal studies. It can interfere with the development of the fetus's organs, brain, and skeleton. Women of childbearing age must use effective birth control during treatment and for at least 30 days after stopping the drug. Men taking the drug should use condoms during sex for at least 90 days after their last dose, as the drug can be present in sperm and affect a developing embryo. If you become pregnant while taking this medication, you must notify your healthcare provider immediately.
For the treatment of active CMV retinitis, Valganciclovir starts working at the molecular level almost immediately, but visible improvement in the eye may take several days to weeks. This is why an 'induction' phase of twice-daily dosing for 21 days is typically required to bring the infection under control. In the case of transplant prophylaxis, the drug begins providing protection as soon as therapeutic levels are reached in the blood, usually within the first few days of starting the daily dose. Regular follow-ups with an ophthalmologist or transplant specialist are necessary to confirm the drug is effectively managing the virus.
You should never stop taking Valganciclovir suddenly without your doctor's explicit instructions. For transplant recipients, stopping the drug early can lead to a dangerous 'rebound' CMV infection that can threaten the transplanted organ. For patients with HIV and CMV retinitis, stopping the medication can cause the eye infection to flare up quickly, potentially leading to permanent blindness. Even if you feel better or are experiencing side effects, contact your healthcare provider first. They may need to adjust your dose or switch you to a different medication rather than stopping treatment entirely.
If you miss a dose of Valganciclovir, take it as soon as you remember, provided it is not too close to your next scheduled dose. If it is almost time for your next dose, skip the missed one and continue with your regular schedule. Do not take two doses at once to make up for the one you missed, as this significantly increases the risk of toxic side effects like bone marrow suppression. Consistency is key to keeping the virus suppressed, so try to use a pillbox or alarm to help you remember. If you miss multiple doses, contact your doctor for advice.
Weight gain is not a typical side effect of Valganciclovir; in fact, weight loss is more commonly reported. The drug frequently causes gastrointestinal side effects like nausea, vomiting, and diarrhea, which can lead to a decrease in appetite and weight loss. Some patients also report abdominal pain or a general feeling of being unwell (malaise), which can further reduce food intake. If you notice rapid weight gain or swelling (edema) in your legs or ankles, this could be a sign of kidney problems rather than fat gain, and you should report it to your doctor immediately.
Valganciclovir has several significant drug interactions that require careful management. It should not be taken with imipenem-cilastatin due to a high risk of seizures, and it can cause severe blood problems if taken with zidovudine (AZT). It also interacts with medications like probenecid and mycophenolate mofetil, which can cause the levels of Valganciclovir to rise to dangerous levels. Because it is cleared by the kidneys, any other drug that affects kidney function can also interact with it. Always provide your doctor with a complete list of all medications, supplements, and herbs you are taking.
Yes, Valganciclovir is available as a generic medication in both tablet and oral solution forms. The generic versions are bioequivalent to the brand-name drug Valcyte, meaning they contain the same active ingredient and work the same way in the body. Generic Valganciclovir is typically more affordable than the brand-name version and is widely covered by most insurance plans. When switching to a generic, ensure that the dosage and instructions remain exactly the same as prescribed by your doctor. Both brand and generic versions carry the same serious black box warnings.
Other drugs with the same active ingredient (Valganciclovir)
> Warning: Stop taking Valganciclovir and call your doctor or emergency services immediately if you experience any of the following:
The FDA has issued a 'Black Box Warning' for Valganciclovir due to the following risks:
Report any unusual symptoms to your healthcare provider immediately. Regular blood monitoring is the only way to catch these side effects early.
To ensure safety, patients on Valganciclovir should expect the following monitoring schedule:
Valganciclovir can cause side effects like seizures, dizziness, ataxia (loss of muscle coordination), and confusion. Patients should not drive or operate heavy machinery until they know how the medication affects them and their healthcare provider confirms it is safe to do so.
While there is no direct chemical interaction between alcohol and Valganciclovir, alcohol can cause dehydration and strain the kidneys. Furthermore, both alcohol and Valganciclovir can cause gastrointestinal upset and dizziness. It is generally advised to limit or avoid alcohol consumption while being treated for a serious viral infection like CMV.
Valganciclovir should not be stopped abruptly without consulting a physician. In transplant patients, stopping the drug early can lead to the development of CMV disease. In HIV patients, stopping maintenance therapy can lead to a rapid flare-up of CMV retinitis and permanent vision loss. There is no specific 'withdrawal syndrome,' but the risk of viral rebound is high.
> Important: Discuss all your medical conditions, especially kidney disease or blood disorders, with your healthcare provider before starting Valganciclovir.
For each major interaction, the mechanism usually involves either additive toxicity (two drugs causing the same side effect) or renal competition (two drugs fighting to be excreted by the kidneys). The management strategy usually involves dose reduction, increased monitoring frequency, or choosing an alternative medication.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter drugs.
> Important: Your healthcare provider will evaluate your complete medical history, including any previous drug allergies or blood disorders, before prescribing Valganciclovir.
Valganciclovir is approved for the prevention of CMV disease in pediatric kidney and heart transplant recipients. It is NOT approved for the treatment of congenital CMV (CMV present at birth) or for CMV retinitis in children. The dosing must be meticulously calculated using the BSA/CrCl formula. Long-term safety data regarding growth and development in children are limited, but the risks of bone marrow suppression and potential future infertility remain significant concerns.
Elderly patients are more likely to have age-related decreases in renal function. Since Valganciclovir is renally excreted, the risk of toxic reactions is higher in this group. Clinicians must calculate the Creatinine Clearance (CrCl) rather than just looking at the serum creatinine level, as muscle mass (and thus creatinine production) decreases with age. Dose adjustments are frequently necessary.
Renal impairment is the most critical factor in Valganciclovir dosing. For patients with a CrCl < 60 mL/min, the dosing interval must be extended or the dose reduced (see Usage Instructions). In patients with severe renal failure, the drug can accumulate rapidly, leading to fatal bone marrow failure or seizures.
No specific studies have been conducted in patients with liver disease. However, since the conversion of Valganciclovir to ganciclovir occurs partly in the liver, severe hepatic dysfunction could theoretically affect the rate of active drug formation, though this is not usually a limiting factor in clinical practice.
> Important: Special populations require individualized medical assessment and more frequent lab monitoring to ensure safety.
| Parameter | Value |
|---|---|
| Bioavailability | ~60% (as Ganciclovir) |
| Protein Binding | 1% to 2% |
| Half-life | ~4 hours (normal renal function) |
| Tmax | 1.0 to 2.1 hours |
| Metabolism | Rapid hydrolysis to Ganciclovir (non-CYP) |
| Excretion | Renal >90% (unchanged Ganciclovir) |
Valganciclovir is classified as a Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor. It belongs to the broader category of antiviral agents used for herpesvirus infections. It is chemically related to acyclovir but has a much broader spectrum of activity against CMV.